BioNTech SE
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 22UA.DU | ALBIO.PA | 8247.HK | 1548.HK | BBZA.F | 1355.HK | |
|---|---|---|---|---|---|---|
| Market cap | — | 15.48M | 355.26M | 76.81B | 3.18B | 429.50M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | 1.8 | — | 85.8 | 26.4 | — |
| Price/book | — | 0.4 | 2.7 | 2.4 | 0.9 | -20.0 |
| Dividend yield | — | — | — | — | 3.97% | — |
| 1-year change | −13.92% | +60.78% | +199.39% | +109.10% | 0.00% | +62.84% |
| Today | +2.43% | +2.44% | 0.00% | −0.94% | +1.59% | −0.41% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All 22UA.DU news ›J.P. Morgan Sticks to Their Hold Rating for BioNTech SE (BNTX)
J.P. Morgan analyst Jessica Fye maintained a Hold rating on BioNTech SE today and set a price target of $86.86. According to TipRanks, Fye is a 4-star analyst with an average return of 4.1% and a 52.20% success rate. Fye covers the…
BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
Rising Dragon Acquisition Corp. and HZJL Cayman Limited Announce Mutual Termination of Merger Agreement Cipher, a Prosegur Company, and BIO-key Announce Technology Integration to Expand Identity Security Offering, Starting in Portugal…
BioNTech Q3 2026 Earnings Preview
Preview BioNTech Q3 earnings before market open on Nov. 3, with consensus EPS of €0.76 and revenue of €1,038.48M. - BioNTech (BNTX) is scheduled to announce Q3 earnings results on Tuesday, November 3rd, before market open. The consensus…
BioNTech: Q3 profitability and higher R&D guidance accompanied an accelerating oncology pipeline
TradingView BioNTech: Q3 profitability and higher R&D guidance accompanied an accelerating oncology pipeline Q3 revenue was €1.289 billion and adjusted net profit was €441 million, with results driven b
BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study
The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar. An antibody-drug conjugate from BioNTech and…
BioNTech to test pumitamig-Trodelvy breast cancer combo
Rising Dragon Acquisition Corp. and HZJL Cayman Limited Announce Mutual Termination of Merger Agreement Cipher, a Prosegur Company, and BIO-key Announce Technology Integration to Expand Identity Security Offering, Starting in Portugal…
BioNTech to present 16 cancer abstracts at ESMO 2026
Rising Dragon Acquisition Corp. and HZJL Cayman Limited Announce Mutual Termination of Merger Agreement Cipher, a Prosegur Company, and BIO-key Announce Technology Integration to Expand Identity Security Offering, Starting in Portugal…
BioNTech SE (BNTX) Receives a Buy from Canaccord Genuity
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE, with a price target of $132.00. Newman covers the Healthcare sector, focusing on stocks such as BioNTech SE, Tango Therapeutics, and…
More from 1 other outlet
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
The selection of the XFG variant is based on guidance from the FDA as the preferred composition of COVID-19 vaccines for use in the U.S. beginning in fall 2026.3 This season’s Pfizer and BioNTech COVID-19 vaccine will begin shipping…
More from 1 other outlet
BioNTech's BNT113 Misses Progression-Free Survival Endpoint In Phase 3 Head And Neck Cancer Trial
BioNTech SE (BNTX) announced that its AHEAD-MERIT Phase 2/3 trial evaluating BNT113 in combination with pembrolizumab did not meet the primary endpoint of progression-free survival (PFS) compared with pembrolizumab alone in patients with…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com17
- stocktitan.net10
- markets.businessinsider.com9
- 247wallst.com8
- themarketsdaily.com6
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 83 articles, not a forecast.